Robbins Arroyo LLP Is Investigating the Officers and Directors of Ocular Therapeutix, Inc. (OCUL) on Behalf of Shareholders

SAN DIEGO & BEDFORD, Mass.--()--Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Ocular Therapeutix, Inc. (NasdaqGM: OCUL) breached their fiduciary duties to shareholders. Ocular, a biopharmaceutical company, focuses on the development, manufacture, and commercialization of ocular therapies using its Hydrogel technology.

View this press release on the firm's Shareholder Rights Blog: www.robbinsarroyo.com/shareholders-rights-blog/ocular-therapeutix

Ocular Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Leonid Kandinov at (800) 350-6003, LKandinov@robbinsarroyo.com, or via the shareholder information form on the firm's website.

Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Robbins Arroyo LLP
Leonid Kandinov
LKandinov@robbinsarroyo.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsarroyo.com

Release Summary

Do you own shares of Ocular Therapeutix, Inc.? Robbins Arroyo LLP is investigating claims on behalf of shareholders of Ocular.

$Cashtags

Contacts

Robbins Arroyo LLP
Leonid Kandinov
LKandinov@robbinsarroyo.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsarroyo.com